| References: |
AB-423 is a potent, highly seletive inhibitor of HBV replication through a block of pgRNA encapsidation. AB-423 in combination with EVT has shown synergistic antiviral activity in vitro in primary human hepatocytes. Furthermore, AB-423 alone and in combination with entecavir has shown potent in vivo activity in a hydrodynamic injection (HDI) mouse model of HBV.The HBV capsid inhibitor AB-423 exhibits a dual mode of inhibition:inhibited encapsidation of pgRNA during ongoing infection; inhibited cccDNA synthesis presumably via inhibition of the capsid uncoating step.In vitro AB-423 showed: pan-genotypic activity; potent activity against HBV in combination with Nucs, IFN, and RNAi agents;no significant activity against unrelated viruses. |
